Paul Sweetnam
Gründer bei Response Pharmaceuticals, Inc.
Profil
Paul Sweetnam is the founder of Response Pharmaceuticals, Inc. He worked as Vice President-Research & Technology at Bayer Pharmaceuticals Corp.
He was the Chief Scientific Officer at Surface Logix LLC from 2001 to 2012.
Prior to that, he worked as a Principal at Yale University, the University of Miami, and Pfizer Pharmaceuticals, Inc. He received his undergraduate degree from the University of Maine and his doctorate from Georgetown University.
Aktive Positionen von Paul Sweetnam
| Unternehmen | Position | Beginn |
|---|---|---|
Response Pharmaceuticals, Inc.
 Response Pharmaceuticals, Inc. BiotechnologyHealth Technology Response Pharmaceuticals, Inc. is a clinical-stage therapeutic development company that focuses on developing treatments for weight management and metabolic disease. The company is based in Falls Church, VA. The company's initial clinical focus is to help people taking antipsychotic medications for disabling mental illness combat weight gain and metabolic dysregulation that is endemic with these treatments. Response is developing RDX-002 as an adjunctive therapy for patients taking first-line antipsychotic therapy. The company was founded by Eric Keller, Paul Sweetnam. Eric Keller has been the CEO since incorporation. | Gründer | - |
Ehemalige bekannte Positionen von Paul Sweetnam
| Unternehmen | Position | Ende |
|---|---|---|
Surface Logix LLC
 Surface Logix LLC Pharmaceuticals: MajorHealth Technology Surface Logix LLC is a drug development company which involves biophysical chemistry to create new small molecule drugs. It creates chemical entities and focuses on cardiovascular and metabolic diseases. The company was founded by George M. Whitesides and Carmichael S. Roberts, Jr. and is headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | 03.10.2012 |
University of Miami
 University of Miami Other Consumer ServicesConsumer Services University of Miami (Florida) is a private research university with students from around the world that is focused on teaching and learning, the discovery of new knowledge, and service to the South Florida region and beyond. The university was founded in 1925 and it is headquartered in Coral Gables, FL. | Corporate Officer/Principal | - |
| Yale University | Corporate Officer/Principal | - |
Pfizer Pharmaceuticals, Inc.
 Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Pharmaceuticals, Inc. is an American company that manufactures pharmaceutical products. | Corporate Officer/Principal | - |
| Bayer Pharmaceuticals Corp. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Paul Sweetnam
| University of Maine | Undergraduate Degree |
| Georgetown University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Surface Logix LLC
Surface Logix LLC Pharmaceuticals: MajorHealth Technology Surface Logix LLC is a drug development company which involves biophysical chemistry to create new small molecule drugs. It creates chemical entities and focuses on cardiovascular and metabolic diseases. The company was founded by George M. Whitesides and Carmichael S. Roberts, Jr. and is headquartered in Cambridge, MA. | Health Technology |
| Bayer Pharmaceuticals Corp. | |
Pfizer Pharmaceuticals, Inc.
Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Pharmaceuticals, Inc. is an American company that manufactures pharmaceutical products. | Health Technology |
Response Pharmaceuticals, Inc.
Response Pharmaceuticals, Inc. BiotechnologyHealth Technology Response Pharmaceuticals, Inc. is a clinical-stage therapeutic development company that focuses on developing treatments for weight management and metabolic disease. The company is based in Falls Church, VA. The company's initial clinical focus is to help people taking antipsychotic medications for disabling mental illness combat weight gain and metabolic dysregulation that is endemic with these treatments. Response is developing RDX-002 as an adjunctive therapy for patients taking first-line antipsychotic therapy. The company was founded by Eric Keller, Paul Sweetnam. Eric Keller has been the CEO since incorporation. | Health Technology |
